J17 Capital
Overview
J17 Capital is a private equity firm specializing in growth equity investments, focusing on technology, pharmaceutical, and therapeutic sectors across North America. The firm partners with growth-oriented companies, targeting middle-market to late-stage entities, to provide capital and strategic support. Their investment approach emphasizes collaboration with financial institutions and fintech startups to develop and launch financial operations and products. J17 Capital's portfolio includes companies such as Cambium, GAIB, Osaro, Pell Network, and Shardeum, reflecting their commitment to fostering innovation and growth in diverse industries. The firm's investment philosophy centers on leveraging technology and experience to empower enterprises and financial institutions, aiming to maximize return on investment while supporting the development of secure and innovative financial solutions.
Investment Focus
- Growth-oriented companies
- Technology, pharmaceutical, or therapeutic sectors
- Middle-market to late-stage entities
Portfolio Companies
Reach J17 Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about J17 Capital
What sectors does J17 Capital invest in?
J17 Capital invests in Technology, Artificial Intelligence, Blockchain, Pharmaceuticals, Networking and Therapeutics, and is based in Ontario, Canada. J17 Capital is listed as a private equity in the ConnectSafely investor database.
What stage does J17 Capital invest at?
J17 Capital backs companies at Seed, Growth and Late Stage, writing cheques of 3M - 100M.
Which regions does J17 Capital invest in?
J17 Capital invests across United States and Canada.
What companies has J17 Capital invested in?
J17 Capital's portfolio includes Shardeum, Cambium, Osaro, Pell Network and GAIB.
Last updated · Source: ConnectSafely investor database
